Trial · NCT02062385
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Severity of Rotavirus Gastroenteritis | V260 With Staggered or Concomitant EPI | 34 | Participants | ||
| Number of Participants With Any Severity of Rotavirus Gastroenteritis | Placebo With Staggered or Concomitant EPI | 109 | Participants | ||
| Percentage of Participants With Elevated Temperature | V260 With Staggered or Concomitant EPI | 21.84 | Percentage of participants | ||
| Percentage of Participants With Elevated Temperature | Placebo With Staggered or Concomitant EPI | 22.83 | Percentage of participants | ||
| Percentage of Participants With Vomiting or Diarrhea | V260 With Staggered or Concomitant EPI | Vomiting | 2.68 | Percentage of participants | |
| Percentage of Participants With Vomiting or Diarrhea | Placebo With Staggered or Concomitant EPI | Vomiting | 3.52 | Percentage of participants | |
| Percentage of Participants With Vomiting or Diarrhea | V260 With Staggered or Concomitant EPI | Diarrhea | 20.15 | Percentage of participants | |
| Percentage of Participants With Vomiting or Diarrhea | Placebo With Staggered or Concomitant EPI | Diarrhea | 20.11 | Percentage of participants | |
| Percentage of Participants With Intussusception | V260 With Staggered or Concomitant EPI | 0.10 | Percentage of participants | ||
| Percentage of Participants With Intussusception | Placebo With Staggered or Concomitant EPI | 0.00 | Percentage of participants | ||
| Number of Participants With Severe Rotavirus Gastroenteritis | V260 With Staggered or Concomitant EPI | 11 | Participants | ||
| Number of Participants With Severe Rotavirus Gastroenteritis | Placebo With Staggered or Concomitant EPI | 52 | Participants | ||
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | V260 With Concomitant EPI | Poliovirus Type 1: Baseline, n=186, 190 | 44.09 | 95% Confidence Interval 36.83 to 51.54 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | Placebo With Concomitant EPI | Poliovirus Type 1: Baseline, n=186, 190 | 38.95 | 95% Confidence Interval 31.97 to 46.27 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | V260 With Concomitant EPI | Poliovirus Type 1: Post OPV #3, n=187, 192 | 98.93 | 95% Confidence Interval 96.19 to 99.87 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | Placebo With Concomitant EPI | Poliovirus Type 1: Post OPV #3, n=187, 192 | 100.00 | 95% Confidence Interval 98.10 to 100.00 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | V260 With Concomitant EPI | Poliovirus Type 2: Baseline, n=186, 190 | 44.09 | 95% Confidence Interval 36.83 to 51.54 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | Placebo With Concomitant EPI | Poliovirus Type 2: Baseline, n=186, 190 | 41.58 | 95% Confidence Interval 34.49 to 48.94 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | V260 With Concomitant EPI | Poliovirus Type 2: Post OPV #3, n=187, 192 | 100.00 | 95% Confidence Interval 98.05 to 100.00 | Percentage of participants |
| Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3 | Placebo With Concomitant EPI | Poliovirus Type 2: Post OPV #3, n=187, 192 | 100.00 | 95% Confidence Interval 98.10 to 100.00 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02062385/results